Why India rejected a patent application for shorter drug-resistant TB treatment
Summary
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
Description from The Hindu.
Who is covering this
-
Why India rejected a patent application for shorter drug-resistant TB treatment | Explained
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
